Today: 9 June 2026
Amphenol stock slips as earnings near — what APH investors watch next week
23 January 2026
1 min read

Amphenol stock slips as earnings near — what APH investors watch next week

New York, January 22, 2026, 20:57 EST — The market has closed for the day.

Amphenol Corp shares dipped 1.36% to close at $152.50 on Thursday, trailing both a rising Wall Street and some of its industrial-electronics rivals. The S&P 500 climbed 0.55%, the Dow added 0.63%, while TE Connectivity nudged up and Eaton slipped, per MarketWatch data.

Amphenol is pulling back ahead of a packed earnings schedule. Zacks Equity Research notes the company will release its fourth-quarter 2025 results on Jan. 28. Over the past month, the consensus earnings-per-share estimate has inched up to 93 cents.

Amphenol has scheduled a conference call for Jan. 28 at 1 p.m. ET, according to its investor calendar. The focus will be on management’s outlook for 2026 demand and whether recent deals will affect the company’s growth trajectory.

The stock climbed 1.49% on Wednesday, ending the day at $154.60 amid a wider rally, nudging it near recent peaks. Trading volume exceeded its 50-day average, according to MarketWatch data.

It dropped 1.33% Tuesday, snapping a two-day rally, though it still outpaced many rivals amid a broader market decline. Trading volume surged past its 50-day average, MarketWatch noted.

Amphenol manufactures connectors, interconnect systems, antennas, sensors, and specialty cables. Its products serve industries such as industrial, defense, commercial aerospace, automotive, mobile networks, and IT and data communications. The company runs three segments, among them Harsh Environment Solutions and Communications Solutions, per Reuters company data.

Earlier this month, Amphenol closed its purchase of CommScope’s Connectivity and Cable Solutions business, projecting around $4.1 billion in sales by 2026. CEO R. Adam Norwitt highlighted that the acquisition “adds significant fiber optic interconnect capabilities” for IT datacom and communications networks. The company also expects the deal to boost 2026 diluted EPS by roughly $0.15, not counting acquisition-related costs. Amphenol Investors

Traders are expected to zero in on revenue growth, operating margins, and shifts in order trends linked to data-center expansions and aerospace and defense projects. Investors usually drill down on “organic” growth — the gains from the core business, excluding acquisitions.

Amphenol reported record sales of $6.2 billion for the third quarter of 2025, marking a 53% jump in U.S. dollars. Adjusted diluted EPS came in at $0.93. The company also boosted its quarterly dividend by 52%, raising it to $0.25 per share.

Expectations can swing either way. Any cautious comments on near-term demand, margin hits from integration costs, or disappointing results from newer ventures could drag the shares down, particularly after a rally that has pushed the stock close to its peak.

The next key date is Wednesday, when Amphenol releases earnings for Jan. 28, followed by a 1 p.m. ET call where management will outline their immediate plans.

Stock Market Today

  • Wheat Prices Mixed as Winter Wheat Gains on U.S. Crop Progress
    June 9, 2026, 9:22 AM EDT. Wheat markets closed mixed on Monday, with winter wheat futures rising across Chicago and Kansas City exchanges, while Minneapolis spring wheat fell slightly. The U.S. Department of Agriculture's Crop Progress report showed 92% of winter wheat heading, 7% ahead of average, and spring wheat planting at 98%, with improving crop conditions. Export inspections dropped 20.65% from last week but marketing year shipments rose 9.13% compared to last year. Ukraine's wheat crop estimate increased by 1.8 million tonnes to 21.7 million tonnes. Futures finished with Chicago SRW wheat up 1 to 3 ¼ cents and Kansas City HRW wheat up 2 ¼ to 9 cents, contrasting the modest decline in Minneapolis spring wheat.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Previous Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Qualcomm stock price ticks up as QCOM lines up Feb. 4 earnings — what traders watch next
Next Story

Qualcomm stock price ticks up as QCOM lines up Feb. 4 earnings — what traders watch next

Go toTop